Novacyt subsidiary fined for HSE breach at 'historical operation'.
Novacyt said on Friday that its Lab 21 Healthcare subsidiary has been fined £52,000 following the conclusion of a Health and Safety Executive prosecution relating to historical operations at its former Axminster site.
Novacyt S.A. (CDI)
12 September 2025 12:18:58
Source: Sharecast
The AIM-traded molecular diagnostics group said the sentencing hearing took place on 11 September, after Lab 21 pleaded guilty in March to health and safety charges over its use of biological agents at the site between June 2018 and April 2019.
Novacyt said the court granted full recognition for Lab 21’s early guilty plea and confirmed that the fine would be paid from existing cash resources, adding that it did not materially affect the group’s financial position.
The company said the ruling “now concludes this process, with no further liability or legal action expected in relation to this case”.
At 1116 BST, shares in Novacyt were down 0.83% at 40.41p.
Reporting by Josh White for Sharecast.com.
N/A
ISIN:
N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes
Compare our accounts
If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.
Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.
